POWW Investors Have Opportunity to Lead AMMO, Inc. Securities Fraud Lawsuit with the Schall Law Firm – AMMO (NASDAQ:POWW)

Photo of author

By Ronald Tech

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AMMO, Inc. (“Ammo” or “the Company”) POWW for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s securities between August 19, 2020 and September 24, 2024, inclusive (the “Class Period”), are encouraged to contact the firm before November 29, 2024.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Ammo failed to maintain appropriate controls over financial reporting. Due to these failures, the Company was likely to misstate related party transactions from 2020 to 2023. The Company failed to appropriately value unrestricted stock awards to executives and employees from 2020 to 2022. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Ammo, investors suffered damages.

See also  3 Stock Spinoffs Poised for Market Domination
The Forgotten Gold Mine: Hidden Value in Spinoff Stocks

Spinoff stocks have long been cast aside by investors, deemed as unwanted remnants of bigger entities. However, diving deep into the world of spinoffs reveals a treasure trove waiting to be discovered. As investing guru Joel Greenblatt highlights in his timeless masterpiece "You Can Be a Stock Market Genius," these castaways often harbor unrealized potential when set free.

Solventum (SOLV): A Diamond in the Rough

Solventum (NYSE:SOLV) emerges as a promising player in the healthcare landscape after being spun off from industrial giant 3M (NYSE:MMM). With a stronghold in sterilization devices, dressings, tapes, this $8.2 billion revenue giant is ready to conquer. Despite a sluggish start post-separation, boasting revenues of $2 billion and $2.08 per share earnings, the stock remains undervalued. Priced at a discount due to an $8.3 billion debt burden from its previous parent, Solventum is on the path to redemption, making it a beacon in the sea of mediocrity.

Kenvue (KVUE): Unleashing Consumer Power

Kenvue (NYSE:KVUE) struts into the consumer health sector post its emancipation from Johnson & Johnson (NYSE:JNJ). The custodian of iconic brands like Tylenol, Listerine, or Band-Aid, this $15 billion powerhouse flexes its muscles. With a formidable dividend legacy inherited from its erstwhile parent, Kenvue stands tall despite a 24% drop since its inception. Like a phoenix rising from the ashes, Kenvue is poised to soar high on the wings of trust and quality.

W.K. Kellogg (KLG): A Breakfast of Champions

If you had cereal for breakfast, chances are it bore the imprint of W.K. Kellogg (KLG). Stepping out of the shadows of its parent, this stalwart in the breakfast food industry is no stranger to your morning routine. With a legacy as rich as your favorite cornflakes, W.K. Kellogg is a stock to watch, destined to nurture portfolios much like it nurtures bodies.

The Rise of W.K. Kellogg in a Shrinking Cereal Market The Rise of W.K. Kellogg in a Shrinking Cereal Market

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Market News and Data brought to you by Benzinga APIs